An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk

[...]Model 2 [Figure 1C–D] and Model 3 [Figure 1E–F] achieved 100% specificity in predicting efficacy and were able to independently predict CAR-T-cell therapy efficacy, with a P-value of 0.001 [Supplementary Table 5, http://links.lww.com/CM9/C191]. [...]while the choice of costimulatory domain might affect CAR-T-cell therapy efficacy, our study did not address this potential influence. [...]our research successfully developed and validated an index system for assessing the efficacy of CD19 CAR-T-cell therapy in patients with r/r DLBCL. Funding This work was supported by grants from the National Key R&D Program of China (No. 2021YFA1100800), National Natural Science Foundation of China (Nos. 81830004 and 82070168), Translational Research Grant of NCRCH (No. 2020ZKZC04), Shanghai Municipal Health Commission (No. 2020CXJQ02), and Cultivation project of National Natural Science Foundation of Shanghai Tongji Hospital (No.